Notably, in ovarian cancer cells, BPA activates the PI3K/Akt signaling pathway; analogues such as BPS and BPF display comparable estrogenic potency, while BPAF often exceeds BPA in ERα activation, suggesting their potential oncogenicity. Here, ESR1 is linked to ovarian carcinoma.